Both our study and those of Gabrilovich highlight an LD-mediated mechanism of CD8+ T cell response regulation and suggest potential therapeutic avenues, including the targeting of LPCAT2-mediated LD accumulation, as a druggable mechanism to restore CRC cell sensitivity. Here, LPCAT2 is linked to colorectal carcinoma.